Clinical trials: Pioglitazone, completed
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
The purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (QD) combined with a thiazolidine taken QD in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318070
- Testing
- Alogliptin and pioglitazone, Pioglitazone
- Volunteers
- 339 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Study In People With Type 2 Diabetes
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
- Trial name
- NCT00196989
- Testing
- Pioglitazone, GW677954
- Where
- 143 sites in United States, Argentina and 11 more
- Volunteers
- 448 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
The proposed investigation is a Phase 1 trial to determine the safety, tolerability, and maximum tolerated dose (MTD) of the combination of pioglitazone ( and carboplatin patients with advanced or metastatic solid malignancies.
- Trial name
- NCT02133625
- Testing
- carboplatin, pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Obesity, Metabolic Syndrome
Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
The purpose of the study was to determine the effects of growth hormone and an insulin sensitizer drug in pre-diabetic adults with excessive amounts of abdominal fat.
- Conditions
- Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
- Trial name
- NCT00352287
- Testing
- Recombinant human growth hormone; pioglitazone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Stanford University
Healthy
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
The objective was to investigate the effect of different doses of BI 10773 on the bioavailability of pioglitazone after multiple oral doses of both drugs
- Trial name
- NCT02172235
- Testing
- Pioglitazone, Pioglitazone - low dose, BI 10773 - low dose
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
Metabolic Syndrome, Bipolar Depression
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance.
- Conditions
- Metabolic Syndrome, Bipolar Depression, Insulin Resistance
- Trial name
- NCT00835120
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University Hospitals Cleveland Medical Center
Polycystic Ovarian Syndrome
Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome
Objective: 1. To investigate the changes in the levels of interleukin-6 and interleukin-8 after 3 months treatment with metformin alone and combination of metformin and pioglitazone in patients with polycystic ovarian syndrome…
- Trial name
- NCT03117517
- Testing
- Metformin, Metformin, Pioglitazone
- Where
- Pakistan
- Volunteers
- 106 people
- Sponsor
- Khyber Medical University Peshawar
Nonalcoholic Steatohepatitis
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
- Trial name
- NCT00227110
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes, Insulin Resistance
Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance
The objective of this study is to determine whether targeted pharmacological improvement of insulin sensitivity will normalize the associated elevations of thrombotic and inflammatory cardiovascular disease (CVD) biomarkers in…
- Conditions
- Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
- Trial name
- NCT00443755
- Testing
- metformin, pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Diabetes Mellitus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.
- Trial name
- COMPLEMENT (NCT00672919)
- Testing
- Pioglitazone
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
In the treatment of type 2 diabetes (T2D), the number of patients requiring combination therapy of oral antidiabetic agents (OADs) is more than 70%.
- Trial name
- NCT04013581
- Testing
- TZD group, SGLT-2 group
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Yonsei University
Cocaine Use Disorder, Alcohol Use Disorder
PPARγ Agonist Treatment for Cocaine Dependence
The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine…
- Trial name
- NCT02774343
- Testing
- Pioglitazone, Therapy, Contingency Management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 2 Diabetes Mellitus
A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
The purpose of this study is to assess the hypothesis that treatment with study medication (omarigliptin; MK-3102) provides greater reduction in A1C Hemoglobin (a marker of diabetic severity) compared with placebo, after 12 weeks…
- Trial name
- NCT01217073
- Testing
- Omarigliptin, Pioglitazone, Metformin
- Volunteers
- 685 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Liver
Safety Study of Pioglitazone Compared To Glyburide on Liver Function
The purpose of this study is to determine the liver safety of pioglitazone, once daily (QD), versus glyburide taken with metformin and insulin.
- Trial name
- NCT00494312
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 2,120 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes
The purpose of the study is to determine the efficacy of alogliptin compared to placebo when given alone or as add-on therapy to metformin or add-on to pioglitazone (with or without metformin).
- Trial name
- NCT01289119
- Testing
- Alogliptin, Metformin, Pioglitazone
- Where
- 21 sites in China, Hong Kong and 1 more
- Volunteers
- 506 people
- Sponsor
- Takeda
Healthy Volunteers
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
The purpose of this study is to assess the relative bioavailability and bioequivalence of 2 strengths of the FDC tablet product SYR-322-4833 BL compared to the individual alogliptin and pioglitazone tablets in healthy Russian…
- Trial name
- NCT03501277
- Testing
- Alogliptin, Pioglitazone, SYR-322-4833 BL
- Where
- Russia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Takeda
Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated
Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.
This is a phase 2 study conducted in two sequential stages: The first stage is an Italian single institution, single arm, pilot study, aimed at exploring the activity of the combination T and P in myxoid liposarcoma patients who…
- Conditions
- Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell
- Trial name
- TRABEPIO (NCT04794127)
- Testing
- Trabectedin, Pioglitazone Oral Product
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy…
- Trial name
- NCT00909597
- Testing
- pioglitazone, taspoglutide
- Where
- 147 sites in United States, Australia and 17 more
- Volunteers
- 756 people
- Sponsor
- Hoffmann-La Roche
HIV Lipodystrophy
Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
The purpose of this study is to determine whether patients with HIV lipodystrophy (fat wasting) benefit from taking the combination of two drugs, one insulin sensitizer (either metformin or pioglitazone, both diabetes drugs) and…
- Trial name
- NCT00362440
- Testing
- Leptin, Pioglitazone or metformin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center